TABLE 1.
Baseline demographics and disease characteristics of patients with solid tumors treated with ONO‐4578
|
Monotherapy N = 10 |
Combination therapy N = 21 |
|
|---|---|---|
| Median age, years (range) | 57 (41–73) | 59 (33–73) |
| Male, n (%) | 5 (50) | 13 (62) |
| ECOG PS, n (%) | ||
| 0 | 3 (30) | 12 (57) |
| 1 | 7 (70) | 9 (43) |
| Cancer type, n (%) | ||
| Bile duct | 1 (10) | 4 (19) |
| Breast | 0 (0) | 2 (10) |
| Colorectal | 2 (20) | 3 (14) |
| Ovarian | 1 (10) | 0 (0) |
| Pancreatic | 1 (10) | 5 (24) |
| Prostate | 1 (10) | 0 (0) |
| Small cell lung | 0 (0) | 1 (5) |
| Other solid tumors | 4 (40) a | 6 (29) b |
| Number of prior regimens, n (%) | ||
| 0 | 0 (0) | 1 (5) c |
| 1 | 0 (0) | 1 (5) |
| 2 | 2 (20) | 5 (24) |
| 3 | 3 (30) | 3 (14) |
| ≥4 | 5 (50) | 11 (52) |
| Prior radiotherapy | 4 (40) | 9 (43) |
Abbreviation: PS, performance status.
a
Included alveolar soft part sarcoma, cervical cancer, medulloblastoma, and urothelial cancer.
b
Included ameloblastoma, apocrine adenocarcinoma, cervical cancer, gallbladder cancer, thymic cancer, and uterine body cancer.
c
A patient with ameloblastoma had not received a prior therapy due to the lack of standard therapy.